PURPOSE Previous studies suggest that vascular endothelial growth factor (VEGF) circulating levels might improve identification of patients with prostate cancer but results are conflicting. Our aim was to compare serum VEGF levels across different prostate pathologies (including benign prostatic hyperplasia, prostatitis, high grade prostate intraepithelial neoplasia and prostate cancer) in pati...

Background: Different studies assessed the role of inflammation in malignancy of different organs. Prostatitis has been suggested as a cause of cancer and BPH. Till now, more than 100 types of human Papilloma virus (HPV) are recognized including low and high-risk groups for carcinogenesis. Among them HPV-16 and HPV-18 have shown further association with cancer. Regarding the pr...

Prostate artery embolization (PAE) has emerged as a promising treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). We aim to provide an up-to-date review of this minimally invasive technique, including discussion of potential benefits and technical challenges. Current evidence suggests it is a promising and effective option for patients with large prostate...

Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA (cfDNA), its comparison with prostate-specific antigen (PSA) level in prostate cancer screening and also in patients with localized ...

Objective: To evaluate the efficacy of drug in improving lower urinary tract symptoms for improved health care and better management patients. Study Design: Randomized controlled trial Place Duration Study: Department Urology, General Medicine Surgery, Pakistan Ordinance Factories Hospital, Wah Cantt from 1st January 2021 to 31st July 2022. Methodology: One hundred patients, age more than 45 ye...

Benign Prostatic Hyperplasia and Prostate Cancer The symptoms associated with benign prostatic hyperplasia can also be caused by prostatic cancer, though they are far more likely to be due to benign overgrowth. Men with BPH do not have a higher incidence of prostate cancer (Coley 1997). The relatively high rate of prostate cancer in the general population, however, requires that an accurate dia...

Prostatomegaly is one of the most common conditions affecting the ageing male. The effects of prostatomegaly on voiding function, however, vary greatly from patient to patient and thus make measuring its impact a challenging task. Three most common causes of prostate enlargement are benign prostatic hyperplasia (BPH), prostate cancer and Prostatitis. Prostatomegaly affects the function of ureth...

Dutasteride is a competitive inhibitor of the enzyme 5-alpha-reductase and commonly used to treat symptoms benign prostatic hyperplasia (BPH).
 Objective: determine efficacy safety dutasteride in terms indicators that are important clinical practice.
 Data sources. The literature was searched using search «prostate hyperplasia», hypertrophy», «dutasteride», «quality life», «adverse dr...

Background Information: Currently alpha1-adrenoreceptor blockers with the combination of 5- alpha reductase inhibitors are widely used as first-line therapy to improve Lower urinary tract symptoms (LUTS) associated Benign Prostatic Hyperplasia (BPH). Aims And Objectives:The aim this study was evaluate Efficacy drug Silodosin and Dutasteride in patients mild severe symptoms. Materials Methods:Th...

Background and Objective: Benign Prostatic Hyperplasia (BPH) is defined as the enlargement of prostate gland in presence urinary symptoms without any evidence malignancy. For patients who have failed medical treatment first line therapy, surgical intervention will be administered treatment. Hemorrhage one most dreadful serious complications surgery. Bleeding can often significant lead to increa...